Anti-PD-1 and Bleomycin Cause Lung Injury in Mice
Author Information
Author(s): Wang Fei, Deng Haiyi, Zhou Maolin, Yang Yilin, Zhou Jiankui, Wang Yansheng, Xie Xiaohong, Lin Xinqing
Primary Institution: First Affiliated Hospital of Guangzhou Medical University
Hypothesis
Does GSDME-mediated pyroptosis contribute to lung injury caused by anti-PD-1 treatment in mice?
Conclusion
The study found that GSDME-mediated pyroptosis is linked to increased lung injury when anti-PD-1 is combined with bleomycin in mice.
Supporting Evidence
- Anti-PD-1 treatment combined with bleomycin led to more severe lung inflammation and fibrosis in mice.
- High levels of caspase-3 and GSDME were found in the lung tissue of treated mice.
- SP600125, a JNK inhibitor, reduced lung damage by inhibiting pyroptosis.
- RNA sequencing showed upregulation of pyroptosis-related genes in lung tissue from ICI-LI patients.
Takeaway
When mice were given a drug that helps fight cancer, it made their lungs hurt more when they also got another medicine that causes lung damage.
Methodology
Mice were treated with bleomycin and anti-PD-1 antibodies, followed by assessments of lung function, histology, and gene expression.
Limitations
The complexity of ICI-LI mechanisms cannot be fully replicated in vitro.
Statistical Information
P-Value
0.04
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website